Status:

UNKNOWN

The Effects of Omega-3 Fatty Acids on Metabolic Syndrome

Lead Sponsor:

University of Washington

Collaborating Sponsors:

Pfizer

National Institutes of Health (NIH)

Conditions:

Metabolic Syndrome X

Eligibility:

All Genders

18-75 years

Phase:

EARLY_PHASE1

Brief Summary

The purpose of this study is to determine the effects of omega-3 fatty acids in the form of fish oil supplementation (approximately 2 grams per day) on the carotid intima-media (CIMT)progression (prim...

Detailed Description

This translational pilot study will have a double-blind, placebo-controlled, parallel design. We will enroll one hundred subjects who meet at least 3 of the 5 criteria for metabolic syndrome as per NC...

Eligibility Criteria

Inclusion

  • Adults with Metabolic Syndrome (meets 3 of the following 5)
  • Abdominal obesity, waist circumference in men greater than 40 in. \& in women greater than 35 in.
  • Serum triglycerides greater than or = 150 mg/dL (1.7 mmol/L)
  • Serum HDL cholesterol less than or = 40 mg/dL in men and less than 50 mg/dL in women
  • Blood pressure greater than or = 130/85 mmHg or drug treatment for elevated blood pressure
  • Fasting plasma glucose greater than 100 mg/dL

Exclusion

  • Diabetes
  • Known or documented CHD (including ECG consistent with prior MI), CVA (including TIA), PVD (including symptoms of claudication)
  • Angina or other chest pain that may indicate CHD
  • Clinically significant neoplastic, cardiovascular, hepatic, renal, metabolic, endocrine (untreated or unstable), or psychiatric (untreated or unstable)
  • Known abnormal LFTS greater than 2X ULN
  • Smoker, illicit drug use, or excessive alcohol use
  • Medications: Lipid lowering therapy, daily NSAID or greater than 325 mg ASA (PRN use ok), clopidogrel (or equivalent), Coumadin, Omega-3 fatty acid supplement, other investigational drugs within 30 days of study entry, high omega-3 fatty acid content in diet within past three months
  • Pregnancy or planning pregnancy during the study period
  • Sensitivity or allergy to fish

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2012

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00350194

Start Date

October 1 2006

End Date

June 1 2012

Last Update

March 2 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Northwest Lipid Research Clinic (University of Washington Affiliated)

Seattle, Washington, United States, 98104